Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has been nominated for the 2024 Biotech Trophy award, organized by the France Biotech industry association.
The award recognizes a biotech company which has distinguished itself in the past two years by particularly remarkable advances in R&D, operational development, partnerships or financing.
This nomination reflects the progress made by Vect-Horus in the domain of drug delivery of therapeutic drugs to the central nervous system (CNS) and the recent signing of two major licensing agreements with Novo Nordisk and Ionis Pharmaceuticals. As a result, Vect-Horus has become a key global player in this field.
“We are proud to be recognized by France Biotech for our technology and its potential to significantly improve the treatment of CNS disorders,” said Alexandre Tokay co-founder and CEO of Vect-Horus. “Our technology has been validated by the recent signature of two major licensing agreements, and offers the ability to facilitate the brain targeting of therapeutic drugs and imaging agents.”
The award winner will be announced on March 25th.
